Good morning, you're tuned in to Markets Desk.
Canada's trade battle with the United States is playing out differently depending on which province you're watching. Alberta is taking a softer diplomatic line with Washington, with its top U.S. envoy arguing the approach is earning the province real access. Meanwhile, Bombardier is under direct fire — Trump threatened Monday to ban the sale of the Canadian planemaker's aircraft in the U.S., calling them not good enough. Bombardier responded by touting its American jobs, a classic playbook move when a foreign manufacturer needs political cover fast.
Shifting to artificial intelligence and Europe's ambitions there, Mistral has closed a record three billion euro funding round led by Samsung, pushing its valuation to twenty-four billion dollars. The French company is betting on open-weight models to carve out space between OpenAI and Anthropic, and this round signals serious institutional conviction that Europe can field a genuine competitor in this race.
And in pharma, Novartis has suffered a setback in the cholesterol drug space, specifically around compounds targeting Lp-a levels. That failure raises the pressure considerably on Amgen and Eli Lilly, both of whom have significant capital committed to proving that lowering Lp-a actually translates into fewer cardiac events in patients.
That's the tape. Markets Desk, signing off the floor.
